FGF23 c-tail fusion proteins

US10464979B2 · kind B2 · utility

Assignees

• NEW YORK UNIVERSITY · US
• PFIZER INC. · US

Inventors

• Moosa Mohammadi · Scarsdale, US
• Regina Goetz · New York, US
• Jeanne MAGRAM · Croton-on-Hudson, US
• Kristen Johnson · San Diego, US

Key dates

• Filing date: Mar 30, 2015
• Grant date: Nov 5, 2019
• Expiry date: Mar 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.